{"id":"tp-40904","type":"article-newspaper","title":"Xencor Shares Climb 23.94% on XmAb819 Kidney Cancer Results","author":"Enna Lee","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/investing/40904","datePublished":"2026-10-26T09:46:57.000Z","dateModified":"2026-10-26T09:46:57.000Z","language":"en","abstract":"A Phase 1 study showed a 45.5% response rate in advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration.","section":"Investing","references":[]}